Skip to main content
. Author manuscript; available in PMC: 2020 Dec 27.
Published in final edited form as: Leukemia. 2020 Jun 27;34(10):2749–2753. doi: 10.1038/s41375-020-0940-8

Table 3.

Univariate and multivariate for progression and death

Univariate Multivariable
Outcome Risk factor Level N Events HR (95% CI) p-value (95% CI) p-value
Progression to any PCD Glycosylation No glycosylation 389 38 Reference Reference
Glycosylation 25 12 6.4 (3.3, 12.4) <0.001 7.8 (4.0, 15.3) <0.001
Mayo Risk Group11 0 factors 161 11 Reference Reference
Any 1 factor 144 13 1.4 (0.6, 3.2) 0.398 1.2 (0.5, 2.7) 0.648
Any 2 factors 63 13 3.7 (1.6, 8.2) 0.002 3.2 (1.4, 7.2) 0.005
Any 3 factors 16 10 13.3 (5.0, 31.4) <0.001 13.4 (5.6, 32.0) <0.001
Progression or death Glycosylation No glycosylation 389 307 Reference Reference
Glycosylation 25 22 1.6 (1.1, 2.5) 0.027 1.6 (0.99, 2.5) 0.051
Mayo Risk Group11 0 factors 161 118 Reference Reference
Any 1 factor 144 117 1.2 (0.9, 1.5) 0.224 1.2 (0.9, 1.5) 0.267
Any 2 factors 63 56 1.4 (1.03, 2.0) 0.033 1.4 (1.02, 1.9) 0.041
Any 3 factors 16 15 1.7 (0.98, 2.9) 0.060 1.7 (0.98, 2.9) 0.060

Mayo risk factors for progression from MGUS to myeloma and related conditions:11 free light chain ratio abnormal, M-spike ≥ 1.5, heavy chain isotype not IgG